Drugs / ACT#001-PSMA CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07240857 | Apr → Oct 2026 expected | castration-resistant prostate carcinoma | Zhejiang University | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT#001-PSMA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07240857 ↗ |
| Known as | ACT#001 | “This study is designed to evaluate the safety and efficacy of local injection of ACT#001 chimeric antigen receptor T cells (ACT#001-PSMA CAR-T) in the treatment of...” NCT07240857 ↗ |
| Modality | Cell therapy | “ACT#001 chimeric antigen receptor T cells (ACT#001-PSMA CAR-T)” NCT07240857 ↗ |
| Route | Other | “Under ultrasound guidance, CAR-T cells are injected into the prostate or localized lesions via the rectum or perineum” NCT07240857 ↗ |